Treatment with the monoclonal antibodies Casirivimab and Imdevimab seems most effective in COVID-19 patients who haven't yet elicited an immune response to the disease.
Arthritis Drug Tocilizumab Presents Promise for COVID-19 Pneumonia Treatment
Tocilizumab, the drug used to treat rheumatoid arthritis might also have therapeutic value for COVID-19 patients who have developed or at high risk of developing serious lung damage from SARS-CoV-2 infections.
Tocilizumab, the drug used to treat rheumatoid arthritis might also have therapeutic value for COVID-19 patients who have developed or at high risk of developing serious lung damage from SARS-CoV-2 infections.
‘Monoclonal antibodies treat COVID-19 patients effectively with greatest reduction in viral load and better outcomes.’
Read More..
Results show that 3% of patients in the antibody group and 6% in the placebo group required at least one medical visit through day 29. Among those who were negative for SARS-CoV-2 antibodies at baseline, the proportions were 6% vs. 15%. In addition, patients who had the highest viral load at baseline saw the greatest reductions in viral load by day 7.Read More..
Tocilizumab, the anti–interleukin-6 receptor monoclonal antibody could improve outcomes in hospitalized adults with COVID-19 pneumonia who are not on mechanical ventilation. In an industry-supported, international trial in the New England Journal of Medicine, around 400 patients were randomized to standard care either alone or with one or two doses of tocilizumab.
Results show that primary efficacy outcome significantly favored the tocilizumab group (12% vs. 19% with standard care alone).
Mortality alone did not differ significantly between the groups. The trial emphasized enrollment of racial/ethnic minority groups, and the results were consistent among Blacks, Latinx patients, and American Indian/Alaska Natives.
Advertisement
